We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPIRI.L Regulatory News (PIRI)

  • There is currently no data for PIRI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

28 Jul 2016 11:29

RNS Number : 5266F
Pires Investments PLC
28 July 2016
 

 

Pires Investments PLC

("Pires" or the "Company")

 

Unaudited interim results for the six months to 30 April 2016

 

Chairman's Statement

 

During the period under review the Company continued to incur significant losses though at a lower rate than during the previous twelve months. Operating costs were lower during the period but the full benefit of the cost reduction programme referred to with the results for the year ended 31 October 2015 and announced in April this year had not begun to come through. Costs it is hoped will be significantly lower in the future.

Overall our investments suffered some diminution in value though this was very largely again due to a further drop in value of our holding in Rame Energy plc ("Rame"), about which more will be said below. In respect of our other holdings, our holding in SalvaRx Group plc ("SalvaRx") showed a further modest increase in value as did that in Kennedy Ventures plc ("Kennedy"), though both have fallen back somewhat since the end of the period. Armstrong Ventures plc ("Armstrong") (now called EVR Holdings plc) announced a reverse transaction but the shares unfortunately fell in price on the announcement of this transaction.

In operational terms, positive progress was made in three of our other investee companies. In March a reverse takeover was completed into the then 3Legs Resources plc to acquire SalvaRx Limited, a cancer immunotherapy development group, as described in our full year results issued on 29 April 2016. Since then two particular developments have been announced - the awarding of an Euro 8.3m EU grant to the consortium of which they are a part to take one of SalvaRx's products through phase 2 human testing and an investment in a further cancer drug development company, Intensity Therapeutics Inc, whose lead product is planned to enter human clinical trials this year.

Kennedy, which acquired a tantalite project in Namibia in 2015, began mining in the final months of 2015. It has very recently completed subject to shareholder approval a £2m equity raise to enable it to upgrade its tantalite recovery and to begin work on a potentially valuable lithium deposit that has been discovered in association with the tantalite.

Armstrong announced, just before the end of the period under review the reverse takeover of MelodyVR Limited which provides virtual reality music devices and content. This transaction has been approved by Armstrong shareholders and implemented, along with a change of name to EVR Holdings plc.

Our holdings in Kennedy and Armstrong are relatively small and we have in part profitably realised these investments and will likely continue to divest these holdings.

The performance of Rame, our largest holding, has been particularly disappointing. Having announced their intention to raise up to £2.8m of new equity on 28 April 2016, they have not to date done so and were unable to produce their results within the timescale set by the AIM rules. As a result their shares were suspended on 1 July 2016 and remain so today. The Board is not able to provide any clarification as to when and how this situation is likely to be resolved.

As previously indicated, we continue to seek a single investment or reverse opportunity if possible on a share-for-share basis and we have made further reductions in our operating costs.

The Company has been operating on limited cash resources for some time. In the Circular of 11 March 2016, the Company announced that, as an initial step towards delivering the strategy mentioned in the last paragraph, the Board was proposing to seek to raise fresh equity capital which was expected to be sufficient to enable the Company to investigate suitable opportunities and undertake adequate due diligence in order to move towards execution of a significant acquisition. However, it was later decided by the Board to undertake a smaller capital raise of £100,000, through a subscription at 4.73p, principally subscribed by our largest shareholder, Ambrosia Investment Limited ("Ambrosia"), which now has a 28.8 % holding in the Company.

 

In view of the position of the Company's investment portfolio and in particular the suspension of trading in the shares of Rame, the Board has arranged a working capital facility, which will be in the form of a convertible unsecured loan note or a similar instrument, with its major shareholder, Ambrosia, up to the value of £200,000 that may be drawn down over a period of eighteen months and will not be repayable until a significant transaction or equity fundraising has been completed.

 

Conversion of the unsecured loan note (and any interest) may not occur to the extent that, immediately following such conversion, the new fully paid shares which are the subject of such conversion to be issued to the noteholder would carry 30% or more of the voting rights of the Company, unless such conversion is affected as part of a sale of the entire issued share capital of the Company or is part of a mandatory offer for the remaining shares in the Company, under Rule 9 of the Takeover Code.

 

It is not of course possible in view of its present shareholding position for Ambrosia to subscribe for significantly more ordinary shares without triggering a bid obligation.

 

As Ambrosia is a related party, the independent directors of the Company, having consulted with our nominated adviser, believe that the terms of the facility are fair and reasonable insofar as shareholders are concerned.

 

Peter Redmond

Chairman

 

 

Enquiries:

 

Pires Investments plc

Peter Redmond, Director

 

 

Tel: +44 (0) 20 7917 1817

Nominated Adviser

Cairn Financial Advisers LLP

Liam Murray

 

 

Tel: +44 (0) 20 7148 7900

Broker

Peterhouse Corporate Finance

Duncan Vasey / Lucy Williams

 

Tel: +44 (0) 20 7469 0935

Tel: +44 (0) 20 7469 0936

 

 

 

UNAUDITED STATEMENT OF COMPREHENSIVE INCOME

for the six months ended 30 April 2016

Unaudited

Unaudited

Audited

6 months

6 months

Year

ended

ended

Ended

30-Apr

30-Apr

31-Oct

2016

2015

2015

Continuing activities

£

£

£

Notes

Revenue

Investment income

-

-

134

Other income

13

8,314

6,200

Total revenue

13

8,314

6,334

(Losses) on investments held at fair value through profit or loss

(22,843)

(218,172)

(80,380)

Operating expenses

(130,980)

(145,518)

(380,652)

Operating (loss) from continuing activities

(153,810)

(355,376)

(454,698)

(Loss) before taxation from continuing activities

(153,810)

(355,376)

(454,698)

Tax

342

-

-

(Loss) for the period and total comprehensive income attributable to equity holders of the Company

(153,468)

(355,376)

(454,698)

Basic (loss) per share

3

Equity holders

Basic and diluted

(0.006p)

(0.015p)

(0.019p)

 

UNAUDITED STATEMENT OF FINANCIAL POSITION

As at 30 April 2016

Unaudited

Unaudited

Audited

As at

As at

As at

30-Apr

30-Apr

31-Oct

2016

2015

2015

£

£

£

Notes

NON-CURRENT ASSETS

Property, plant and equipment

503

1,610

1,057

Investment in subsidiaries

1

-

-

TOTAL NON CURRENT ASSETS

504

1,610

1,057

CURRENT ASSETS

Investments

483,093

561,040

516,520

Trade and other receivables

35,818

138,014

50,561

Cash and cash equivalents

52,681

99,897

61,825

TOTAL CURRENT ASSETS

571,592

798,951

628,906

TOTAL ASSETS 

572,096

800,561

629,963

EQUITY 

Called up share capital

11,853,192

11,853,192

11,853,192

Share premium account

2,904,840

2,904,840

2,904,840

Retained earnings

(14,483,815)

(14,299,349)

(14,398,671)

Capital redemption reserve

164,667

164,667

164,667

TOTAL EQUITY

4

438,884

623,350

524,028

LIABILITIES

CURRENT LIABILITIES

Trade and other payables 

133,212

177,211

105,935

TOTAL LIABILITIES AND CURRENT LIABILITIES

133,212

177,211

105,935

TOTAL EQUITY AND LIABILITIES

572,096

800,561

629,963

 

UNAUDITED CASH FLOW STATEMENT

For the six months ended 30 April 2016

 

Unaudited

Unaudited

Audited

6 months

ended

6 months

ended

Year ended

ended

30-Apr

30-Apr

31-Oct

2016

2015

2015

£

£

£

Notes

Cash flows from operating activities

5

Net cash absorbed by operating activities

(38,586)

(123,015)

(335,219)

Cash flows from investing activities

Payments to acquire investments

-

(80,600)

(80,600)

Proceeds of sale of investments

10,587

-

182,312

Disposal of subsidiary

18,500

-

-

Finance income received

355

-

134

Other income received

-

8,314

-

Net cash (used in)/from investing activities

29,442

(72,286)

101,846

Cash flows from financing activities

Net repayments on borrowings

-

-

-

Finance costs paid

-

-

-

Net cash from financing activities

-

-

-

Net (decrease) in cash and cash equivalents during the period

(9,144)

(195,301)

(233,373)

Cash and cash equivalents at beginning of the period

61,825

295,198

295,198

Cash and cash equivalents at end of the period

52,681

99,897

61,825

 

Notes to the Unaudited Interim Report

 

1. GENERAL INFORMATION

 

Pires Investments PLC (the "Company") is a company domiciled in England whose registered office address is c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2M 1QS. The condensed interim financial statements of the Company for the six months ended 30 April 2016 is that of the Company only. The Company disposed of its subsidiary, (Ventec Renewable Energy Limited), in February 2016. The condensed interim financial statements for the six months ended 30 April 2015 are those of the Group which had a subsidiary during that period.

 

The condensed consolidated interim financial statements do not constitute statutory accounts as defined in Section 434 of the Companies Act 2006.

 

The financial information for the year ended 31 October 2015 has been extracted from the statutory accounts for that period which were prepared in accordance with International Financial Reporting Standards ("IFRS"). The auditors' report on the statutory accounts was unqualified. A copy of those financial statements has been filed with the Registrar of Companies.

 

The financial information for the six months ended 30 April 2014 and 2015 was also prepared in accordance with IFRS.

 

The condensed consolidated interim financial statements do not include all of the information required for full annual financial statements. 

 

The condensed interim financial statements were authorised for issue on 30 July 2016.

 

 

2. BASIS OF ACCOUNTING

 

The consolidated financial statements are unaudited and have been prepared on the historical cost basis in accordance with International Financial Reporting Standards as adopted by the EU ("IFRS") using the same accounting policies and methods of computation as were used in the annual financial statements for the year ended 31 October 2015. As permitted, the interim report has been prepared in accordance with the AIM rules for Companies and is not compliant in all respects with IAS 34 Interim Financial Statements. The condensed consolidated interim financial statements do not include all the information required for full annual financial statements and hence cannot be construed as in full compliance with IFRS.

 

 

3. LOSS PER SHARE

 

The calculation of the basic loss per share is based on the following data:

 

Unaudited

Unaudited

Audited

6 months

6 months

Year

ended

ended

ended

30-Apr

30-Apr

31-Oct

2016

2015

2015

£

£

£

Profit/(loss) on continuing activities after tax

(153,468)

(355,376)

(454,698)

 

Basic and fully diluted

Basic and fully diluted (loss)/earnings per share have been computed based on the following data:

 

Number of shares

Weighted average number of ordinary shares for the period

2,321,659,864

2,321,659,864

2,321,659,864

Basic (loss)/earnings per share from continuing activities (p)

(0.006)

(0.015)

(0.019)

 

There were no dilutive instruments that would give rise to diluted earnings per share

 

 

 

 

 

 

 

4. STATEMENT OF CHANGES IN EQUITY

 

Share Capital

Share Premium

Capital Redemption Reserve

Retained Earnings

Total

£

£

£

£

£

At 1 November 2014

11,853,192

2,904,840

164,667

(13,943,973)

978,726

Loss for the 6 months ended 30 April 2015

 

 

(355,376)

(355,376)

At 30 April 2015

11,853,192

2,904,840

164,667

(14,299,349)

623,350

Loss for the 6 months ended 31 October 2015

(99,322)

(99,322)

At 31 October 2015

11,853,192

2,904,840

164,667

(14,398,671)

524,028

At 31 October 2015

Loss for the 6 months ended 30 April 2016

(153,468)

(153,468)

Adjustment re disposal of subsidiary

68,324

68,324

At 30 April 2016

11,853,192

2,904,840

164,667

(14,483,815)

438,884

 

 

 

5. NOTES TO THE CASH FLOW STATEMENT

 

Unaudited

Unaudited

Audited

6 months

6 months

Year

ended

ended

ended

30-Apr

30-Apr

31-Oct

2016

2015

2015

£

£

£

Cash flow from operations

Profit/(loss)

(153,468)

(355,376)

(454,698)

Depreciation

553

553

1,106

Realised loss/(gain) on investments

-

-

(38,969)

Fair value movements in investments

22,843

218,172

119,349

Finance income

(355)

(8,314)

(134)

(Increase)/decrease in receivables

40,522

(15,619)

71,835

Increase/(decrease) in payables

51,319

37,569

(33,708)

Cash flow from operations

(38,586)

(123,015)

(335,219)

 

 

 

6. DISTRIBUTION OF INTERIM REPORT

 

Copies of the Interim Report for the six months ended 30 April 2016 can be obtained from the Registered Office during normal business hours and are available on the Company's website, www.piresinvestments.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR SESFSAFMSEEW
Date   Source Headline
18th Oct 20231:27 pmRNSNew Investment by SVV UK Software Technology Fund
11th Oct 20237:00 amRNSSmarttech247 Group PLC - Investee Company Update
11th Oct 20237:00 amRNSHolding(s) in Company
11th Oct 20237:00 amRNSHolding(s) in Company
9th Oct 20233:31 pmRNSResult of AGM & Change of Name
28th Sep 20238:09 amRNSHolding(s) in Company
27th Sep 20237:00 amRNSHalf-year Report
12th Sep 20237:00 amRNSNotice of AGM & Proposed Change of Name
28th Jun 20237:01 amRNSFinal Results
25th May 202310:05 amRNSHolding(s) in Company
25th May 20237:00 amRNSInvestment portfolio update
27th Apr 202311:59 amRNSSure Ventures PLC - Investee Company Update
31st Mar 20237:00 amRNSLandVault raises additional $3 million in funding
20th Mar 20233:35 pmRNSHolding(s) in Company
23rd Feb 20237:00 amRNSInvestment in the SVV III Limited Partnership
27th Jan 20237:00 amRNSHolding(s) in Company
22nd Dec 202211:22 amRNSTwo-year £1.235 million Unsecured Loan Facility
15th Dec 20228:44 amRNSSmarttech247 admitted to trading on AIM
14th Dec 202211:03 amRNSSVV Software Fund invests in Jaid
2nd Dec 20229:07 amRNSHolding(s) in Company
1st Dec 20227:12 amRNSSmarttech247 announces Intention to Float on AIM
30th Nov 20223:26 pmRNSResult of AGM
10th Nov 202211:14 amRNSHolding(s) in Company
10th Nov 202211:10 amRNSHolding(s) in Company
10th Nov 202211:03 amRNSHolding(s) in Company
7th Nov 20227:00 amRNSPosting of Notice of AGM
31st Oct 20227:00 amRNSNew SVV1 Investment in EVERYANGLE
25th Oct 202212:28 pmRNSUpdate on Investment in Pluto Digital plc
29th Sep 20227:00 amRNSHalf-year Report
1st Aug 20227:00 amRNSPlacing, RPTs, Warrants & Directors’ dealings
22nd Jul 202210:15 amRNSCompany and Investment Portfolio Update
21st Jul 20221:30 pmRNSResults of Court Meeting & GM & Lapsing of Scheme
15th Jul 20223:02 pmRNSDisclosure under Rule 20.3(b): DirectorsTalk video
12th Jul 202211:11 amRNSTR-1 Notification
11th Jul 20222:00 pmRNSDisclosure under Rule 20.1
6th Jul 20228:09 amRNSRule 2.9 Announcement Update
4th Jul 20227:00 amRNSConditional Warrant Exercise
1st Jul 20227:00 amRNSForm 8.3 - Pires Investments PLC
30th Jun 20223:48 pmRNSExercise of Warrant
28th Jun 20225:00 pmRNSNotice of Tern General Meeting
28th Jun 20224:05 pmRNSPublication and posting of the Scheme Document
27th Jun 20227:00 amRNSInvestment Portfolio Update
22nd Jun 202212:34 pmRNSDisclosure under Rule 20.1
22nd Jun 202212:10 pmRNSDisclosure under Rule 20.1
21st Jun 20222:59 pmRNSTR1 - Notification of Major Holdings
21st Jun 20228:49 amRNSUpdate on Irrevocable Undertaking
21st Jun 20228:44 amRNSForm 8 (DD) - Pires Investments plc
21st Jun 20228:42 amRNSRule 2.9 Announcement - Update
16th Jun 20222:39 pmRNSForm 8.3 - Pires Investments plc
16th Jun 20227:00 amRNSExercise of Warrant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.